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Abstract
Background Autism is a complex polygenic neurodevelop-
mental disorder characterized by deficits in communication
and social interactions as well as specific stereotypical
behaviors. Both genetic and environmental factors appear to
contribute to the pathogenesis of autism. Accumulating data
including changes in immune responses, linkage to major
histocompatibility complex antigens, and the presence of
autoantibodies to neural tissues/antigens suggest that the
immune system plays an important role in its pathogenesis.
Summary In this brief review, we discuss the data regarding
changes in both innate and adaptive immunity in autism
and the evidence in favor of the role of the immune system,
especially of maternal autoantibodies in the pathogenesis of
a subset of patients with autism. The rationale for possible
therapeutic use of intravenous immunoglobulin is also
discussed.
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Introduction
A complex polygenic neurodevelopmental disorder, autism
is characterized by deficits in communication and social
interactions as well as specific stereotypical behaviors. It is
perhaps the most common pediatric disorder, occurring in 1
in 160 children. Both genetic and environmental factors
appear to play an important role. Because the response to
environmental factors is under the regulation of immune
response genes, it is not surprising that a number of
immunological abnormalities and an increased association
with certain major histocompatibility complex (MHC) genes
have been observed in autism. The disorder is three to four
times more common in boys than girls; however, the basis of
preponderance in males is unclear. Immunological abnormal-
ities in both the innate and adaptive immune system that are
manifested by a paradox of immunodeficiency, inflammation,
and autoimmunity have been reported in autism. Immunolog-
ical abnormalities include depressed cell-mediated immunity
and antibody-mediated immunity, increased production of
proinflammatory cytokines and chemokines, and the presence
of autoantibodies against various neural tissues and antigens
(reviewed in Refs. [1–4]).
Furthermore, the presence of autoantibodies against neu-
ronal antigens in mothers of autistic children and in children
withautismandtheinductionofstereotypicalchangesinmice
and rhesus monkeys by autistic maternal immunoglobulin G
(IgG) [5–8] argues in favor of the role of the immune system
in the pathogenesis of a subset of patients with autism.
Therefore, it is not surprising that some studies have reported
the beneficial effect of intravenous immunoglobulin (IVIG).
Here we have reviewed immunological abnormalities in
autism spectrum disorders (ASD) and their response to
biological therapies, with a special emphasis on IVIG.
Because of the space limitation for references, only selected
ones have been cited.
Adaptive Immune Response
Alterations in both T cell- and B cell-mediated immunity in
ASD have been reported. However, these changes are
observed in a subset of patients with ASD.
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Depressed in vitro response to mitogens (phytohemagglu-
tinin [PHA], concanavalin A, pokeweed mitogen) and
recall antigens (mumps, tetanus toxoid, Candida albicans),
and decreased proportions of CD3
+, CD4
+ and CD8
+ T
cells have been reported [1–4]. We also have observed a
decrease in CD8
+CCR7
+CD45RA
–CD8
+ central memory T
cells. Furthermore, there is a shift from Th1 to Th2
cytokine type of CD4
+ and CD8
+cells [9]. Patients with
autism have been shown to have decreased intracellular
interferon-γ (IFN-γ) and interleukin (IL)-2 containing
CD4
+ and CD8
+ T cells, whereas IL-4 containing cells are
increased. In contrast, Singh and colleagues reported
increased plasma levels of IFN-γ (reviewed in Ref. [3]).
However, in CD3 plus CD28-stimulated peripheral blood
mononuclear cell (PBMC) culture supernatants, we did not
observe any increased levels of IFN-γ (Fig. 1a). We also
reported that PHA-induced TNF-α production is increased
in autism [10].
B Cell-Mediated Immunity
Immunoglobulin abnormalities were among the most
common immune abnormalities observed in children with
autism. In 150 patients (compared with the ranges for age-
matched controls), we observed 10 children with common
variable immunodeficiency (CVID), 20 patients with low
total IgG (hypogammaglobulinemia), 4 with IgG subclass
deficiency, and 3 with selective IgA deficiency (<7 mg/dl).
Many of these children had a history of increased episodes of
recurrent upper respiratory tract infections including otitis
media. Furthermore, 10% of children (4 years and older) did
not respond to one or more antigens to immunized antigens.
Forty patients had elevated IgE. However, clinical manifes-
tations of type I hypersensitivity does not appear to be
increased in autism. Also, the proportions and numbers of
circulating B cells appear to be normal. Other investigators
also have reported abnormalities in Ig levels [2, 3]; however,
the frequency of abnormalities is much lower than ours. Our
data may be skewed because patients referred to us have
suspected immunological abnormalities. Many of these
children are on a gluten- and casein-free diet; however, there
is no evidence of an increased incidence of celiac disease
(antibodies to casein, gluten, or tissue transglutamic acid) in
autism.
Autoimmunity in Autism
A theory of autoimmunity in autism has been proposed for
more than 25 years. There appears to be an increased
prevalence of autoimmune disease in family members of
children with autism. Furthermore, there is an increased
incidence of certain MHC genes in children with autism
compared with controls. In 1982, Weizman and colleagues
[11] first reported an abnormal immune response to brain
tissues in children with autism. Since then, a number of
autoantibodies against various neural antigens have been
reported in a large subset of children with autism. These
include myelin basic protein, glial fibrillary acid protein,
and neuron axon filament protein. In addition, antibodies
against nerve growth factor, antibrain endothelial cell
proteins, serotonin receptors, and anti-α2-adrenergic
binding sites have been reported in autism (reviewed in
Ref. [3]). One of the most intriguing observations is that we
did not find an increased frequency of non-organ-specific
autoantibodies (e.g., antinuclear antibodies (ANA), rheu-
matoid factor (RF)) in children with autism (S. Gupta,
unpublished personal observation).
In addition to the presence of autoantibodies in children
with autism, Warren and colleagues [12] were the first to
suggest a role of maternal antibodies in the pathogenesis of
the disorder. They demonstrated the presence of autoanti-
bodies in maternal serum that reacted with the lymphocytes
of affected children. However, Dalton and associates [5]
were the first to demonstrate the presence of antibodies in
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Fig. 1 Production of IL-17 (a)
and IFN-γ (b) from anti-CD3
plus anti-CD28 monoclonal
antibody-stimulated
mononuclear cells from autism
[17] and controls [15]
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Purkinje neurons and other large ones in the adult rat
cerebellum and brainstem, neonatal cerebellum, and surface
antigens of neuroblastoma cell line NB-1. When autism
maternal serum was injected into pregnant mice, the
offspring reported behavioral changes and a modest
reduction in the concentrations of choline and creatine
relative to water; no changes were seen in the controls.
Singer and colleagues [6] performed an exhaustive
analysis of autism maternal antibodies for their reactivity
to fetal, adult human, and rodent brain tissues. Using
homogenates of whole brain tissue or tissue from a specific
area of the brain, they reported reactivity with 36-, 39-, and
61-kDa antigens of human fetal brain. A significant
correlation was observed between mothers having offspring
with autistic disorder and the presence of serum antibodies
against 39- and 36-kDa antigens, but not with antibodies
against 61-kDa antigens. However, these antibodies did not
predict the outcome of future offspring. Therefore, it is
likely that a complex interaction between maternal anti-
bodies and genetic factors, rather than the direct effect of
maternal antibodies, plays a role in the pathogenesis of
autism. No antibodies to myelin basic protein (MBP), glial
fibrillary acid protein (GFAP), or nerve growth factor were
observed in the maternal serum of children with autism.
Braunschweig and colleagues [7] reported reactivity of
maternal serum of children with autism (11.5%) with both
37- and 73-kDa antigens of fetal human brain but not adult
human brain. In addition, the presence of these two
antibodies was associated with behavioral regression. These
investigators then examined whether autism maternal anti-
bodies would induce behavioral changes in rhesus monkeys
[8]. They purified IgG from mothers of children with autism
who were positive for antibodies against fetal human brain
antigens and from mothers of normally developing children
and then administered the IgG to four pregnant rhesus
monkeys. Five untreated pregnant monkeys were also
included in the control group. Monkeys born to mothers
administered with autism maternal serum demonstrated
increased whole body stereotypies across multiple testing
paradigms.Thesemonkeys werealsohyperactive.Incontrast,
monkeys born to mothers treated with IgG from mothers of
normally developing children and untreated monkeys did not
show any significant changes in stereotypies.
Association with MHC
Additional evidence of the role of the immune system in
autism comes from an association of autism with certain
MHC genes. An association was shown with the C4b null
allele of the C4b gene, the extended haplotype B44-S30-
DR4 (44 allele of the HLA-B, the S allele of the BF gene,
the 3 allele of CD4A, the C4b null allele, and the DR4
allele), which is in linkage disequilibrium with MHC class
III and with the third hypervariable region of DRβ1 allele
[13]. The strongest association has been observed between
the null allele of C4b in MHC class III region and autism.
These authors suggested that the low levels of C4 may be
important in the pathogenesis of autism because C4 has
been observed in developing brain neurons. It is interesting
that the allele for TNF-α gene is also located in MHC class
III just telomeric to C4, and TNF-α production is increased
in autism. HLA-DR4 also has been observed with an
increased frequency in mothers of children with ASD and
in their sons with autism [14].
Innate Immune Response
Natural killer (NK) cells, antigen-presenting cells (APC),
and complement proteins are critical components of innate
immunity. More than 20 years ago, Warren and associates
described decreased NK cell cytotoxicity in children with
autism. More recently, Enstrom et al. [15] analyzed gene
expression and functions of NK cells in children with ASD.
An increased expression of genes for killer cell immuno-
globulin receptors and for perforin and granzyme was
observed in ASD. An increased expression of both perforin
and granzyme in NK cells in ASD was confirmed by flow
cytometry. They also observed that baseline as well as
stimulated NK cell cytotoxicity activity was significantly
reduced in ASD. Total hemolytic complement (CH50) and
C3 are normal; however, levels of total C4, particularly C4b,
are significantly lower in autism compared with controls.
Dendritic Cells
Macrophages and dendritic cells (DCs) are two major
APCs; DCs prime naive T cells to differentiate into Th1,
Th2, Th17, and Treg cells, whereas macrophages promote
effector functions of primed T cells [16]. The differentiation
of naive CD4
+ T cells to different subsets by DC is
mediated by distinct cytokines and distinct transcription
factors. Using lineage-specific markers and markers specif-
ic for myeloid DCs (mDCs) and plasmacytoid DCs (pDCs),
we analyzed subpopulations of DCs in the peripheral blood
of children with autism. No significant difference was
observed in the proportions of mDCs and pDCs between
autism and controls (Fig. 2). Because IL-17 (Th17) plays an
important role in autoimmunity and inflammation and there
is evidence of increased autoimmunity in autism, we
examined the production of IL-17 by T cells. No significant
difference was observed in IL-17 production by PBMCs
stimulated with anti-CD3 plus anti-CD28 monoclonal
antibody (Fig. 1b). Similar results were reported by Onore
and colleagues [17] in PHA-stimulated PBMCs. Because
IL-23 promotes the production of IL-17, the researchers
S92 J Clin Immunol (2010) 30 (Suppl 1):S90–S96examined the production of IL-23 by PBMC stimulated
with PHA. They reported a significantly decreased produc-
tion of IL-23 in the ASD group. However, when data are
analyzed for individual patients, the levels of IL-23 are
within the range for healthy controls. In contrast, Jyonouchi
et al. [18] reported an increase in lipopolysaccharide (LPS)-
induced IL-23 production in children with ASD. The
reasons for this discrepancy remain unclear. There are no
published data on Treg cells in ASD.
Monocyte/Macrophages
Increased monocyte counts have been reported in children
with autism compared with controls. In addition, increased
levels of proinflammatory cytokines and chemokines,
including IL-1β, IL-6, TNF-α, macrophage chemoattrac-
tant (MCP)-1, and macrophage inflammatory protein
(MIP)-1β in the cerebrospinal fluid (CSF), and activation
of microglia and astroglia in patients with ASD have been
reported [19–21]. We first reported an increased production
of LPS-activated peripheral blood macrophage-derived
TNF-α in patients with autism [10]. Enstrom et al. [22]
and Jyonouchi et al. [18] reported an increased production
of IL-1β, IL-6, TNF-α, and GM-CSF production by
monocytes stimulated with Toll-like receptor ligands in
ASD. Many of these cytokines may be considered neuro-
poietic cytokines. For example, IL-6 can directly affect
neurons and glial cells and regulate their growth, survival
and death, and neurite outgrowth. TNF-α can induce
behavioral changes and reduce cerebral blood flow. We
also observed significantly increased plasma levels of IL-6,
TNF-α, and MCP-1 in children with autism compared with
controls (Fig. 3). These data suggest that innate immune
response may play a role in the pathogenesis of ASDs.
Biological Therapy in Autism
Several biological treatments have been used in treating
autism. Some of these studies have been published and
others have been presented at various conferences
(reviewed in Ref. [4]). These include transfer factor,
fibroblast growth factor, and IVIG. IVIG has been used in
children with autism based on the rationale of the presence
of antibody deficiency and autoimmunity in autism;
however, data on the beneficial effects are conflicting.
Gupta et al. [1] in an open-label study of 10 children with
autism (nine aged 2 to 6 years and one aged 12 years) and
IgG, IgG subclass deficiency, specific antibody deficiency,
or common variable immunodeficiency were treated with
IVIG at 400 mg/kg/4 weeks for 6 months to 18 months. A
significant improvement in behavioral characteristics, eye
contact, social interactions, and echolalia were observed.
Expressive speech improved in two patients. The 12-year-
old patient displayed minimal improvement after 1 year of
therapy. These data suggest that IVIG may be beneficial in
younger children with autism. Furthermore, we have
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better response (S. Gupta, unpublished observation). Oleske
[23] treated 27 children (aged 2 to 10 years) with autism
who also had low IgG (5), low IgG subclass (12), and
specific antibody deficiency with recurrent infections (10),
with IVIG (400 mg–1 g/kg/3 weeks for 6–18 months).
Twenty-one of the 27 children showed improvement in
autistic behavior. Boris et al. [24] treated 26 patients with
autism (aged 3–17 years; average 6.7 years) with IVIG at
400 mg/kg/4 weeks for six infusions. No immunological
profile was documented. A significant improvement
(ANOVA) was observed in total aberrant behavior score
as well as in hyperactivity, inappropriate speech, irritability,
lethargy, and stereotypy. Possible mechanisms for the
beneficial effects seen may be due to the replacement effect
of IVIG on recurrent upper respiratory tract infections
(during infections autistic behaviors worsen), and the
immunomodulatory effects of IVIG on autoantibodies and
inflammatory cytokines (e.g., inhibits TNF-α production).
Plioplys [25] treated 10 children with autism (4–17 years;
three children of 4–6 years) with normal serum immuno-
globulins. The actual IVIG dose administered ranged from
154 to 375 mg/kg at 6-week interval. The number of
infusions ranged from 1 to 6. Six of ten children received
four infusions, and one child each had one, three, five, and
six infusions. One patient showed significant improvement,
with almost complete amelioration of autistic symptoms.
DelGiudice-Asch et al. [26] treated five children with
autism with IVIG at 400 mg/kg/month for 6 months. Using
10 assessment scales, only the Ritvo-Freeman Real Life
Rating Scale, the sensory response, showed a clinically
meaningful response. Therefore, three studies of 63 subjects
(two studies of 37 patients included subjects who had
underlying Ig-specific antibody deficiency) demonstrated
significant improvement, whereas one study of 10 subjects
with unconventional dosing and intervals and a short 6-week
duration, and another study of 5 patients in a 6-month
treatment did not show significant improvement.
The Primary Immunodeficiency Committee of the
American Academy of Allergy, Asthma, and Immunology
listed autism among the disorders that are unlikely to
benefit from IVIG treatment [27]. The committee cited the
two above-mentioned negative studies [25, 26]—the first
with 10 cases with unconventional dosing, interval, and a
small number of IVIG infusions [25], and the second [26]
with five cases—without citing the original study of 15
patientswithpositiveresults[1]. Therefore, such a conclusion
by the committee appears to be unjustified because more
studies of large numbers of patients treated with an
appropriate dosage of IVIG and for longer durations
demonstrated beneficial effects [1, 23, 24]. Based on the
above data, such a conclusion is unjustified.
Interestingly, Perlmutter et al. [28], in a double-blind
controlled study, reported the beneficial effect of high-dose
IVIG in obsessive-compulsive disorder and tic disorders,
including pediatric autoimmune neuropsychiatric disorders
associated with streptococcal infections. Zykov et al. [29]
in an open-label study reported the beneficial effect of IVIG
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S94 J Clin Immunol (2010) 30 (Suppl 1):S90–S96treatment in patients with Tourette’s syndrome who had
serum antibodies to caudate nucleus.
Because patients with autism display IgG or IgG
subclass deficiency, the presence of autoantibodies, and an
increased production of proinflammatory cytokines and
chemokines, and IVIG is used as a replacement therapy and
plays an important immunomodulatory role in autoantibody
production and proinflammatory chemokine and cytokine
secretion, a good rationale exists for the use of IVIG in at
least a subset of patients with autism. Therefore, there is a
need for a well-designed controlled study to determine the
efficacy of IVIG in ASDs.
Summary
ASD are associated with dysregulated immune responses
represented with a paradox of deficient T cell- and B cell-
mediated responses, increased inflammatory mediator pro-
duction in both the periphery and the brain, and the
presence of autoantibodies against various neural tissues
and antigens in the serum of children with ASD and in the
serum of their mothers. These abnormalities are observed in
a subset of patients and their mothers. A role of the immune
system (especially autoantibodies) in a subset of patients is
supported by the induction of stereotypies and hyperactivity
in mice and rhesus monkeys by the administration of
serum/IgG from mothers of children with autism who are
positive for antibodies against neural antigens. A role of
autoimmunity is further supported by the increased fre-
quency of certain alleles in class II and class III regions of
MHC in children with autism as well as in the mothers of
children with autism. Because of Ig/antibody deficiency
and autoimmunity in autism, there is a rationale for the
therapeutic use of IVIG in autism; however, the results of
open-label and uncontrolled studies are conflicting, which
may be due to differences in patient age, the presence or
absence of Ig/antibody deficiency and/or autoantibodies,
and dosing and duration of IVIG treatment. Thus, there is a
need for a well-controlled double-blind clinical trial with
replacement and immunomodulatory doses of IVIG in ASDs.
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